BioMarin Pharmaceutical (NASDAQ:BMRN) Releases Earnings Results, Beats Expectations By $0.25 EPS

BioMarin Pharmaceutical (NASDAQ:BMRN) announced its quarterly earnings data on Thursday. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25, FiscalAI reports. The firm had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.36% and a net margin of 2.14%.BioMarin Pharmaceutical’s quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.44 earnings per share. BioMarin Pharmaceutical updated its FY 2026 guidance to 4.900-5.100 EPS.

Here are the key takeaways from BioMarin Pharmaceutical’s conference call:

• Second-quarter revenue rose 20% year over year to nearly $1 billion, supported by broad-based demand and the Amicus contribution. BioMarin raised its full-year revenue, VOXZOGO revenue, and non-GAAP EPS guidance.
• The Amicus integration is progressing ahead of expectations, with projected peak revenue of $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI/OPFOLDA, plus approximately $220 million in annual cost synergies by 2028. Management expects meaningful EPS accretion beginning in 2027 and deleveraging roughly one year earlier than previously anticipated.
• VOXZOGO revenue increased 14% year over year, while treated children grew more than 20% globally despite a new U.S. competitor. Approximately 90% of U.S. patients remained on therapy, and BioMarin submitted a supplemental application for hypochondroplasia approval, potentially supporting a 2027 launch.
• BioMarin added BMN 820, an oral CCR2 inhibitor in Phase III development for focal segmental glomerulosclerosis, to its late-stage pipeline. The company also expects to pursue additional clinical-stage business-development opportunities over the next 12 to 18 months.
• Acquisition financing is increasing annual interest expense by approximately $200 million, or $50 million per quarter, while reduced cash balances are lowering interest income. These factors, along with higher operating expenses, contributed to lower year-over-year non-GAAP diluted EPS in the quarter.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $63.81 on Friday. The stock has a market cap of $12.33 billion, a price-to-earnings ratio of 172.46, a PEG ratio of 0.47 and a beta of 0.24. BioMarin Pharmaceutical has a 52 week low of $49.26 and a 52 week high of $66.28. The company’s 50-day moving average price is $58.19 and its 200 day moving average price is $57.06. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. The Goldman Sachs Group started coverage on shares of BioMarin Pharmaceutical in a research note on Monday, May 11th. They set a “neutral” rating and a $69.00 price target on the stock. HC Wainwright raised their price objective on shares of BioMarin Pharmaceutical from $50.00 to $60.00 and gave the company a “neutral” rating in a research note on Friday. Royal Bank Of Canada decreased their price objective on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Morgan Stanley increased their target price on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a report on Friday. Finally, Oppenheimer lifted their price target on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $87.86.

Key BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMRN. Viking Global Investors LP increased its stake in shares of BioMarin Pharmaceutical by 13.8% during the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after purchasing an additional 1,488,552 shares in the last quarter. AQR Capital Management LLC lifted its stake in BioMarin Pharmaceutical by 12.7% in the 4th quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company’s stock valued at $395,197,000 after buying an additional 754,807 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in BioMarin Pharmaceutical by 48.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock valued at $197,405,000 after buying an additional 1,076,568 shares in the last quarter. Vestal Point Capital LP grew its holdings in BioMarin Pharmaceutical by 261.4% during the 4th quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock valued at $178,290,000 after buying an additional 2,170,000 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in BioMarin Pharmaceutical by 0.4% during the 3rd quarter. Northern Trust Corp now owns 1,662,268 shares of the biotechnology company’s stock valued at $90,028,000 after buying an additional 7,157 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.